A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy")
- PMID:17383105
- DOI: 10.1016/j.neuroscience.2007.02.032
A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy")
Abstract
The drug 3,4 methylenedioxymethamphetamine (MDMA; ecstasy) has a widely documented ability to increase feelings of love and closeness toward others. The present study investigated whether oxytocin, a neuropeptide involved in affiliative behavior, may play a role in this effect. A moderate (5 mg/kg, i.p.) dose of MDMA increased social interaction in male Wistar rats, primarily by increasing the amount of time rats spent lying adjacent to each other. MDMA (5 mg/kg) activated oxytocin-containing neurons in the supraoptic and paraventricular nuclei of the hypothalamus, as shown by Fos immunohistochemistry. MDMA (5 mg/kg i.p.) also increased plasma oxytocin levels and this effect was prevented by pre-treatment with the 5-HT(1A) antagonist N-[2-[4-(2-methyoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide maleate salt (WAY 100,635; 1 mg/kg i.p.). The oxytocin receptor antagonist tocinoic acid (20 microg, i.c.v.) had no effect on social behavior when given alone but significantly attenuated the facilitation of social interaction produced by MDMA (5 mg/kg). The 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino)-tetraline) (8-OH-DPAT, 0.25 mg/kg, i.p.) increased social behavior in a similar way to MDMA and this effect was also significantly attenuated by tocinoic acid. Taken together, these results suggest that oxytocin release, stimulated by MDMA through 5-HT(1A) receptors, may play a key role in the prosocial effects of MDMA and underlie some of the reinforcing effects of the drug.
Similar articles
- MDMA-induced c-Fos expression in oxytocin-containing neurons is blocked by pretreatment with the 5-HT-1A receptor antagonist WAY 100635.Hunt GE, McGregor IS, Cornish JL, Callaghan PD.Hunt GE, et al.Brain Res Bull. 2011 Aug 10;86(1-2):65-73. doi: 10.1016/j.brainresbull.2011.06.011. Epub 2011 Jul 1.Brain Res Bull. 2011.PMID:21745546
- Reduced sensitivity to MDMA-induced facilitation of social behaviour in MDMA pre-exposed rats.Thompson MR, Callaghan PD, Hunt GE, McGregor IS.Thompson MR, et al.Prog Neuropsychopharmacol Biol Psychiatry. 2008 May 15;32(4):1013-21. doi: 10.1016/j.pnpbp.2008.01.014. Epub 2008 Feb 4.Prog Neuropsychopharmacol Biol Psychiatry. 2008.PMID:18302974
- Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat.Morley KC, Arnold JC, McGregor IS.Morley KC, et al.Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jun;29(5):648-57. doi: 10.1016/j.pnpbp.2005.04.009.Prog Neuropsychopharmacol Biol Psychiatry. 2005.PMID:15908091
- 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis.de Boer SF, Koolhaas JM.de Boer SF, et al.Eur J Pharmacol. 2005 Dec 5;526(1-3):125-39. doi: 10.1016/j.ejphar.2005.09.065. Epub 2005 Nov 28.Eur J Pharmacol. 2005.PMID:16310183Review.
- Are there sex differences associated with the effects of ecstasy/3,4-methylenedioxymethamphetamine (MDMA)?Allott K, Redman J.Allott K, et al.Neurosci Biobehav Rev. 2007;31(3):327-47. doi: 10.1016/j.neubiorev.2006.09.009. Epub 2006 Nov 15.Neurosci Biobehav Rev. 2007.PMID:17109962Review.
Cited by
- Chronic cocaine exposure during pregnancy increases postpartum neuroendocrine stress responses.Williams SK, Barber JS, Jamieson-Drake AW, Enns JA, Townsend LB, Walker CH, Johns JM.Williams SK, et al.J Neuroendocrinol. 2012 Apr;24(4):701-11. doi: 10.1111/j.1365-2826.2012.02291.x.J Neuroendocrinol. 2012.PMID:22309318Free PMC article.
- Effects of MDMA and Intranasal oxytocin on social and emotional processing.Kirkpatrick MG, Lee R, Wardle MC, Jacob S, de Wit H.Kirkpatrick MG, et al.Neuropsychopharmacology. 2014 Jun;39(7):1654-63. doi: 10.1038/npp.2014.12. Epub 2014 Jan 22.Neuropsychopharmacology. 2014.PMID:24448644Free PMC article.Clinical Trial.
- MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen Pharmacology.Sáez-Briones P, Hernández A.Sáez-Briones P, et al.Curr Neuropharmacol. 2013 Sep;11(5):521-34. doi: 10.2174/1570159X11311050007.Curr Neuropharmacol. 2013.PMID:24403876Free PMC article.
- Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humans.Kirkpatrick MG, Francis SM, Lee R, de Wit H, Jacob S.Kirkpatrick MG, et al.Psychoneuroendocrinology. 2014 Aug;46:23-31. doi: 10.1016/j.psyneuen.2014.04.006. Epub 2014 Apr 19.Psychoneuroendocrinology. 2014.PMID:24882155Free PMC article.Clinical Trial.
- The Non-Peptide Arginine-Vasopressin v1a Selective Receptor Antagonist, SR49059, Blocks the Rewarding, Prosocial, and Anxiolytic Effects of 3,4-Methylenedioxymethamphetamine and Its Derivatives in Zebra Fish.Ponzoni L, Braida D, Bondiolotti G, Sala M.Ponzoni L, et al.Front Psychiatry. 2017 Aug 14;8:146. doi: 10.3389/fpsyt.2017.00146. eCollection 2017.Front Psychiatry. 2017.PMID:28855876Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases